Navigation Links
MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.

- Building Named After 1982 Nobel Prize Winner for Chemistry, Sir Aaron

Klug -

CAMBRIDGE, England, Oct. 16 /PRNewswire/ -- MedImmune today announced the opening of a new, biologics research and development (R&D) facility in Cambridge, the United Kingdom. Named after the 1982 Nobel Prize Winner for Chemistry, the Aaron Klug Building is a major expansion of MedImmune's existing Granta Park site, further cements the region as a major R&D centre for the company, and provides additional laboratory space for MedImmune's growing scientific staff in Cambridge.

The Aaron Klug Building is a 92,000-square-foot facility containing state-of-the-art laboratories. The facility provides MedImmune with capacity to significantly increase the number of candidate drugs that it can develop each year in order to meet R&D goals.

The expansion forms a key part of MedImmune's growth strategy. Following its acquisition by AstraZeneca in June 2007, MedImmune was consolidated with the former Cambridge Antibody Technology business, along with other areas of biological research being conducted elsewhere within AstraZeneca. Now as AstraZeneca's global biologics unit, MedImmune plays a significant role in AstraZeneca's strategic growth plans -- the aim is to deliver an average of one new biologic product per year from 2013.

Jane Osbourn, site leader and vice president of research, Cambridge, said: "Today, MedImmune has one of the largest and most diverse biologics product pipelines in the biotech and pharmaceutical industries. We want to maximise our potential to develop new and better medicines, so adequate space and resource for R&D is a real priority for us.

"Our experience and expertise in Cambridge means the U.K. team plays a central role in MedImmune's global research activity. The Aaron Klug Building is critical to allowing us to fulfill this role and to achieve our goal of significantly increasing our drug development capabilities," Osbourn added.

The new facility is being inaugurated today with the unveiling of a commemorative plaque by honoured guest, Sir Aaron Klug.

The Aaron Klug Building forms part of MedImmune's wider expansion of its European operations. Its opening follows the recent refurbishment and expansion of one of the company's major production sites in Nijmegen in the Netherlands, where products such as Synagis(R) (palivizumab) and Ethyol(R) (amifostine) are prepared for distribution. Completed in early 2008, the newly refurbished site is capable of producing up to 10 discrete products each year, equating to 6.5 million vials.

About MedImmune

MedImmune is a leading innovation-focused biotechnology company whose mission it is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
2. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
3. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
4. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
5. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
6. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
7. Seneca Valley High School Student Receives Science Award From MedImmune
8. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
9. MedImmune Submits Biologics License Application to FDA for Motavizumab
10. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
11. MedImmune Announces Seven Key Promotions and New Hires
Post Your Comments:
(Date:11/30/2015)... Partnership includes an MPP licen ... niversity , s Solid Drug Nanoparticle (SDN) Technology ... up through cost cuts of priority ... licensees based anywhere in the world will have the right to make, use and ... , where licensees based anywhere in the world will have the right to make, ...
(Date:11/30/2015)... , Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" ... Norman C.W. Wong to its Board of Directors ... to Zenith with a wealth of experience as co-founder of ... biology. --> --> Dr. ... Epigenetics, board of directors. Zenith,s long standing expertise in epigenetics ...
(Date:11/30/2015)... , Nov. 30, 2015  Champions Oncology, Inc. ... and services to personalize the development and use of ... Chief Executive Officer, will be presenting at the LD ... 4:30pm Pacific Standard Time (PST).  The conference, held at ... Los Angeles, CA , will feature 200 small/micro-cap ...
(Date:11/30/2015)... -- HUYA Bioscience International, the leader in accelerating global development ... announced it has signed a Memorandum of Understanding with ... between KDDF and HUYA with the ultimate goal of ... the global market. China,s ... preclinical and clinical stage compounds. The company advances the ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced broader entry into the automotive market ... that match the pace of consumer electronics human interface ... sensors are ideal for the automotive industry and will ... Europe , Japan ...
(Date:10/29/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that it has been selected ... of only three finalists for a 2015 Tekne ... category. The Tekne Awards honor Minnesota ... and leadership. iMedNet™ eClinical  technology ...
Breaking Biology News(10 mins):